摘要
目的:观察异搏定和胺碘酮治疗阵发性室上性心动过速的临床效果。方法:2010年2月-2013年8月收治阵发性室上性心动过速患者48例,随机分为胺碘酮组和异搏定组,各24例,分别给予静注胺碘酮、异搏定进行治疗,观察两组治疗的有效率及心血管不良反应。结果:胺碘酮组治疗有效22例,无效2例,有效率91.7%;异搏定组治疗有效21例,无效3例,有效率87.5%,两组治疗的有效率差异无统计学意义(χ2=0.2233,P>0.05)。胺碘酮组心血管不良反应包括窦性心动过缓1例、窦性停搏1例、低血压2例,不良反应发生率16.67%;异搏定组心血管不良反应包括窦性心动过缓3例、窦性停搏2例、完全性房室传导阻滞2例、低血压4例、休克1例、心功能恶化2例,不良反应发生率58.33%;胺碘酮组心血管不良反应发生率明显低于异搏定组(χ2=8.8889,P<0.01)。结论:胺碘酮治疗阵发性室上性心动过速疗效确切,安全可靠。
Objective:To observe the clinical effect of verapamil and amiodarone in the treatment of paroxysmal supraventricular tachycardia.Methods:48 cases with paroxysmal supraventricular tachycardia were selected from February 2010 to August 2013.They were randomly divided into the amiodarone group and the verapamil group with 24 cases in each.They were respectively given intravenous amiodarone and verapamil treatment.The treatment effective rate and cardiovascular adverse reactions of patients in two groups were observed.Results:In the amiodarone group,22 cases were effective;2 cases were invalid;the effective rate was 91.7%.In the verapamil group,21 cases were effective;3 cases were invalid;the effective rate was 87.5%.The effective rates of two groups were no significant difference(χ 2=0.2233,P>0.05).The cardiovascular adverse reactions in the amiodarone group included 1 case of sinus bradycardia,1 case of sinus arrest,2 cases of hypotension,and the incidence rate of adverse reaction was 16.67%.The cardiovascular adverse reactions in the verapamil group included 3 cases of sinus bradycardia,2 cases of sinus arrest,2 cases of complete atrioventricular block,4 cases of hypotension,1 case of shock,2 cases of cardiac function deterioration,and the incidence rate of adverse reaction was 58.33%.The incidence rate of cardiovascular adverse reaction in the amiodarone group was significantly lower than that of the verapamil group(χ 2=8.8889,P<0.01).Conclusion:Amiodarone in the treatment of paroxysmal supraventricular tachycardia has exact curative effect.It is safe and reliable.
